CN1842334A - 化合物在睡眠障碍治疗中的用途 - Google Patents
化合物在睡眠障碍治疗中的用途 Download PDFInfo
- Publication number
- CN1842334A CN1842334A CNA2004800223860A CN200480022386A CN1842334A CN 1842334 A CN1842334 A CN 1842334A CN A2004800223860 A CNA2004800223860 A CN A2004800223860A CN 200480022386 A CN200480022386 A CN 200480022386A CN 1842334 A CN1842334 A CN 1842334A
- Authority
- CN
- China
- Prior art keywords
- triprolidine
- sleep
- purposes
- active agents
- active component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019116 sleep disease Diseases 0.000 title claims abstract description 27
- 150000001875 compounds Chemical class 0.000 title description 8
- 230000007958 sleep Effects 0.000 claims abstract description 154
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 claims abstract description 138
- 229960001128 triprolidine Drugs 0.000 claims abstract description 136
- 238000000034 method Methods 0.000 claims abstract description 57
- 239000000203 mixture Substances 0.000 claims abstract description 46
- 208000020685 sleep-wake disease Diseases 0.000 claims abstract description 24
- 239000013543 active substance Substances 0.000 claims description 88
- 238000002360 preparation method Methods 0.000 claims description 58
- 150000003839 salts Chemical class 0.000 claims description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 239000003795 chemical substances by application Substances 0.000 claims description 40
- 206010041349 Somnolence Diseases 0.000 claims description 30
- 239000010409 thin film Substances 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 29
- 239000003085 diluting agent Substances 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 26
- 239000012752 auxiliary agent Substances 0.000 claims description 26
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 26
- WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical group Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 claims description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- 239000002552 dosage form Substances 0.000 claims description 23
- 239000008298 dragée Substances 0.000 claims description 23
- -1 Cycloxygenase II Chemical compound 0.000 claims description 22
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 17
- 239000008101 lactose Substances 0.000 claims description 16
- 208000002173 dizziness Diseases 0.000 claims description 13
- 229960003712 propranolol Drugs 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- 239000006188 syrup Substances 0.000 claims description 13
- 235000020357 syrup Nutrition 0.000 claims description 13
- 150000001720 carbohydrates Chemical class 0.000 claims description 12
- 206010022000 influenza Diseases 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 229920002678 cellulose Polymers 0.000 claims description 11
- 239000001913 cellulose Substances 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 10
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 10
- 230000036506 anxiety Effects 0.000 claims description 10
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 10
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 10
- 230000035807 sensation Effects 0.000 claims description 10
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 9
- 229960001680 ibuprofen Drugs 0.000 claims description 9
- 230000036407 pain Effects 0.000 claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 206010011224 Cough Diseases 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 8
- 230000003860 sleep quality Effects 0.000 claims description 8
- 230000000392 somatic effect Effects 0.000 claims description 8
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 claims description 7
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 claims description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims description 7
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 7
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 7
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 208000026935 allergic disease Diseases 0.000 claims description 7
- 230000007815 allergy Effects 0.000 claims description 7
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 claims description 7
- 229960005174 ambroxol Drugs 0.000 claims description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 229960001985 dextromethorphan Drugs 0.000 claims description 7
- 229960002390 flurbiprofen Drugs 0.000 claims description 7
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 7
- 229960002146 guaifenesin Drugs 0.000 claims description 7
- 229960003258 hexylresorcinol Drugs 0.000 claims description 7
- 229960004194 lidocaine Drugs 0.000 claims description 7
- 206010027599 migraine Diseases 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 6
- 230000001387 anti-histamine Effects 0.000 claims description 6
- 239000000739 antihistaminic agent Substances 0.000 claims description 6
- 239000003443 antiviral agent Substances 0.000 claims description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 5
- DBHODFSFBXJZNY-UHFFFAOYSA-N 2,4-dichlorobenzyl alcohol Chemical compound OCC1=CC=C(Cl)C=C1Cl DBHODFSFBXJZNY-UHFFFAOYSA-N 0.000 claims description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 5
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 5
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 5
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 5
- 229960004150 aciclovir Drugs 0.000 claims description 5
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 5
- 229940025084 amphetamine Drugs 0.000 claims description 5
- 229960005274 benzocaine Drugs 0.000 claims description 5
- 229960001803 cetirizine Drugs 0.000 claims description 5
- 238000004132 cross linking Methods 0.000 claims description 5
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 5
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 claims description 5
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 5
- 229960003592 fexofenadine Drugs 0.000 claims description 5
- 229960000905 indomethacin Drugs 0.000 claims description 5
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 5
- 229960000991 ketoprofen Drugs 0.000 claims description 5
- 229940041616 menthol Drugs 0.000 claims description 5
- 229960002009 naproxen Drugs 0.000 claims description 5
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 5
- 229960005489 paracetamol Drugs 0.000 claims description 5
- 229960003908 pseudoephedrine Drugs 0.000 claims description 5
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 229960003708 sumatriptan Drugs 0.000 claims description 5
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 5
- 229960000351 terfenadine Drugs 0.000 claims description 5
- 229940122361 Bisphosphonate Drugs 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 4
- 229960003805 amantadine Drugs 0.000 claims description 4
- 150000004663 bisphosphonates Chemical class 0.000 claims description 4
- 229940112822 chewing gum Drugs 0.000 claims description 4
- 235000015218 chewing gum Nutrition 0.000 claims description 4
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 claims description 4
- 229960001253 domperidone Drugs 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 229960001929 meloxicam Drugs 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 239000003204 tranquilizing agent Substances 0.000 claims description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- 230000001430 anti-depressive effect Effects 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 229960001948 caffeine Drugs 0.000 claims description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 3
- 210000004877 mucosa Anatomy 0.000 claims description 3
- 210000003928 nasal cavity Anatomy 0.000 claims description 3
- 229940097496 nasal spray Drugs 0.000 claims description 3
- 239000007922 nasal spray Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 2
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 claims description 2
- 244000208874 Althaea officinalis Species 0.000 claims description 2
- 235000006576 Althaea officinalis Nutrition 0.000 claims description 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 2
- 244000025254 Cannabis sativa Species 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 241000046691 Daphne odora Species 0.000 claims description 2
- 240000003361 Drimia maritima Species 0.000 claims description 2
- 244000166124 Eucalyptus globulus Species 0.000 claims description 2
- 241000628997 Flos Species 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 2
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims description 2
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 2
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 claims description 2
- GHNYBHXFHIPTEK-UHFFFAOYSA-N Urginea maritima Natural products CC1OC(OC2C(O)C(O)C(OC3CCC4(C)C(C3)C(CC5(O)C4CCC6(C)C(CCC56O)C7=COC(=O)C=C7)OC(=O)C)OC2CO)C(O)C(O)C1O GHNYBHXFHIPTEK-UHFFFAOYSA-N 0.000 claims description 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 claims description 2
- 229960003792 acrivastine Drugs 0.000 claims description 2
- 229960002133 almotriptan Drugs 0.000 claims description 2
- 229960005213 amylmetacresol Drugs 0.000 claims description 2
- CKGWFZQGEQJZIL-UHFFFAOYSA-N amylmetacresol Chemical compound CCCCCC1=CC=C(C)C=C1O CKGWFZQGEQJZIL-UHFFFAOYSA-N 0.000 claims description 2
- 230000000202 analgesic effect Effects 0.000 claims description 2
- 230000000578 anorexic effect Effects 0.000 claims description 2
- 229940069428 antacid Drugs 0.000 claims description 2
- 239000003159 antacid agent Substances 0.000 claims description 2
- 230000001458 anti-acid effect Effects 0.000 claims description 2
- 230000002686 anti-diuretic effect Effects 0.000 claims description 2
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000000924 antiasthmatic agent Substances 0.000 claims description 2
- 229940124538 antidiuretic agent Drugs 0.000 claims description 2
- 239000003160 antidiuretic agent Substances 0.000 claims description 2
- 229960004495 beclometasone Drugs 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 229940097320 beta blocking agent Drugs 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 229960004399 carbocisteine Drugs 0.000 claims description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 2
- 229960004126 codeine Drugs 0.000 claims description 2
- 230000036461 convulsion Effects 0.000 claims description 2
- 239000000850 decongestant Substances 0.000 claims description 2
- 229960001378 dequalinium chloride Drugs 0.000 claims description 2
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001259 diclofenac Drugs 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- 229940044949 eucalyptus oil Drugs 0.000 claims description 2
- 239000010642 eucalyptus oil Substances 0.000 claims description 2
- 229960004396 famciclovir Drugs 0.000 claims description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229940060037 fluorine Drugs 0.000 claims description 2
- 229960002963 ganciclovir Drugs 0.000 claims description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960003088 loratadine Drugs 0.000 claims description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 229960003987 melatonin Drugs 0.000 claims description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 2
- 229960005254 naratriptan Drugs 0.000 claims description 2
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 claims description 2
- 229960003753 nitric oxide Drugs 0.000 claims description 2
- 210000001331 nose Anatomy 0.000 claims description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 2
- 229960003752 oseltamivir Drugs 0.000 claims description 2
- 229960001179 penciclovir Drugs 0.000 claims description 2
- 229960001802 phenylephrine Drugs 0.000 claims description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 229960000329 ribavirin Drugs 0.000 claims description 2
- 229960000888 rimantadine Drugs 0.000 claims description 2
- 229960000425 rizatriptan Drugs 0.000 claims description 2
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 claims description 2
- 239000002911 sialidase inhibitor Substances 0.000 claims description 2
- 229940125725 tranquilizer Drugs 0.000 claims description 2
- 230000002936 tranquilizing effect Effects 0.000 claims description 2
- 229940093257 valacyclovir Drugs 0.000 claims description 2
- 239000000052 vinegar Substances 0.000 claims description 2
- 235000021419 vinegar Nutrition 0.000 claims description 2
- 229960001028 zanamivir Drugs 0.000 claims description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims 2
- 235000010603 pastilles Nutrition 0.000 claims 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 description 44
- 239000000902 placebo Substances 0.000 description 44
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 229960001593 triprolidine hydrochloride Drugs 0.000 description 23
- 239000003826 tablet Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 229920002261 Corn starch Polymers 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 18
- 239000008120 corn starch Substances 0.000 description 18
- 230000002618 waking effect Effects 0.000 description 18
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 17
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 17
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 17
- 238000011160 research Methods 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 15
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 13
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 12
- 239000003086 colorant Substances 0.000 description 12
- 230000002354 daily effect Effects 0.000 description 12
- 239000007916 tablet composition Substances 0.000 description 12
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 11
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 11
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 11
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 235000010980 cellulose Nutrition 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000007937 lozenge Substances 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 235000019615 sensations Nutrition 0.000 description 9
- 229910002012 Aerosil® Inorganic materials 0.000 description 8
- 229960001859 domiphen bromide Drugs 0.000 description 8
- 229960004873 levomenthol Drugs 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- BHQQXAOBIZQEGI-UHFFFAOYSA-N methyl 2-chlorobutanoate Chemical compound CCC(Cl)C(=O)OC BHQQXAOBIZQEGI-UHFFFAOYSA-N 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 7
- RWNDHBXQGJICCE-UHFFFAOYSA-K calcium magnesium octadecanoate carbonate Chemical compound C([O-])([O-])=O.[Mg+2].C(CCCCCCCCCCCCCCCCC)(=O)[O-].[Ca+2] RWNDHBXQGJICCE-UHFFFAOYSA-K 0.000 description 7
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229940085605 saccharin sodium Drugs 0.000 description 7
- 230000004622 sleep time Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 6
- 229960004830 cetylpyridinium Drugs 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229910000831 Steel Inorganic materials 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000002826 coolant Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000010959 steel Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010021006 Tyrothricin Proteins 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 229960002537 betamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229960003291 chlorphenamine Drugs 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 3
- 229960002881 clemastine Drugs 0.000 description 3
- 229930003836 cresol Natural products 0.000 description 3
- 229960002783 dexketoprofen Drugs 0.000 description 3
- DKYWVDODHFEZIM-NSHDSACASA-N dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 description 3
- ZICQBHNGXDOVJF-UHFFFAOYSA-N diamantane Chemical compound C1C2C3CC(C4)CC2C2C4C3CC1C2 ZICQBHNGXDOVJF-UHFFFAOYSA-N 0.000 description 3
- 229960001193 diclofenac sodium Drugs 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000007983 food acid Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 3
- 229960003464 mefenamic acid Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229960002702 piroxicam Drugs 0.000 description 3
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 3
- 229960000371 rofecoxib Drugs 0.000 description 3
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960002871 tenoxicam Drugs 0.000 description 3
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 3
- CUZMOIXUFHOLLN-UMVVUDSKSA-N triprolidine hydrochloride monohydrate Chemical compound O.Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CUZMOIXUFHOLLN-UMVVUDSKSA-N 0.000 description 3
- GSXRBRIWJGAPDU-BBVRJQLQSA-N tyrocidine A Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 GSXRBRIWJGAPDU-BBVRJQLQSA-N 0.000 description 3
- 229960003281 tyrothricin Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- 229960001360 zolmitriptan Drugs 0.000 description 3
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920001685 Amylomaize Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 244000241257 Cucumis melo Species 0.000 description 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 2
- 206010013980 Dyssomnias Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 235000011044 succinic acid Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000009492 tablet coating Methods 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- MPPODKLDCLFLKT-UHFFFAOYSA-N (3-acetyloxy-2-hydroxypropyl) acetate Chemical compound CC(=O)OCC(O)COC(C)=O MPPODKLDCLFLKT-UHFFFAOYSA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- HUDNNLKINUVYCQ-UHFFFAOYSA-N 2-[4-(2-methylpropyl)phenyl]propanoic acid;hydrate Chemical compound O.CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HUDNNLKINUVYCQ-UHFFFAOYSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 229910010413 TiO 2 Inorganic materials 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 108010055615 Zein Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003555 analeptic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000005357 flat glass Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000010321 sleep therapy Methods 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000005496 tempering Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
曲普利啶盐酸盐 | 乳糖 | 预胶化玉米淀粉 | 玉米淀粉 | Ac-di-sol | 硬脂酸镁 | 聚乙烯吡咯烷酮K-29-32 | 片重(mg/) | ||
布洛芬 | 200 | 2.5 | 95.5 | 12 | 48 | 25 | 2 | 15 | 400 |
布洛芬 | 400 | 2.5 | 95.5 | 12 | 48 | 25 | 2 | 15 | 600 |
氟比洛芬 | 50 | 2.5 | 145.5 | 12 | 48 | 25 | 2 | 15 | 300 |
右酮洛芬 | 12.5 | 2.5 | 183 | 12 | 48 | 25 | 2 | 15 | 300 |
双氯芬酸钠 | 75 | 2.5 | 145.5 | 12 | 48 | 25 | 2 | 15 | 325 |
塞米考昔 | 200 | 2.5 | 95.5 | 12 | 48 | 25 | 2 | 15 | 400 |
吲哚美辛 | 50 | 2.5 | 145.5 | 12 | 48 | 25 | 2 | 15 | 300 |
酮洛芬 | 100 | 2.5 | 145.5 | 12 | 48 | 25 | 2 | 15 | 350 |
甲灭酸 | 500 | 2.5 | 148 | 12 | 48 | 25 | 2 | 15 | 750 |
萘普生 | 250 | 2.5 | 95.5 | 12 | 48 | 25 | 2 | 15 | 450 |
罗非考昔 | 12.5 | 2.5 | 183 | 12 | 48 | 25 | 2 | 15 | 300 |
吡罗昔康 | 20 | 2.5 | 175.5 | 12 | 48 | 25 | 2 | 15 | 300 |
替诺昔康 | 20 | 2.5 | 175.5 | 12 | 48 | 25 | 2 | 15 | 300 |
阿斯匹林 | 500 | 2.5 | 148 | 12 | 48 | 25 | 2 | 15 | 750 |
扑热息痛 | 500 | 2.5 | 148 | 12 | 48 | 25 | 2 | 15 | 750 |
曲普利啶盐酸盐 | 二氧化硅气凝胶 | 硬脂酸镁 | 碳酸钙 | 液体葡萄糖(溶胶含量) | 液体糖(溶胶含量) | 矫味剂 | 水(ml) | 聚乙烯吡咯烷酮K29-32 | 锭剂重(mg/) | ||
布洛芬 | 200 | 2.5 | 0.05 | 0.249 | 150 | 700 | 1241 | 7.05 | 47 | 1.5 | 2350 |
布洛芬 | 400 | 2.5 | 0.05 | 0.249 | 150 | 600 | 1141 | 7.05 | 47 | 1.5 | 2350 |
氟比洛芬 | 8.75 | 2.5 | 0.05 | 0.249 | 7.5 | 1010 | 1266 | 7.05 | 47 | 1.5 | 2350 |
右酮洛芬 | 12.5 | 2.5 | 0.05 | 0.249 | 10 | 1010 | 1196 | 7.05 | 47 | 1.5 | 2350 |
双氯芬酸钠 | 75 | 2.5 | 0.05 | 0.249 | 70 | 800 | 1390 | 7.05 | 47 | 1.5 | 2350 |
塞米考昔 | 200 | 2.5 | 0.05 | 0.249 | 150 | 700 | 1241 | 7.05 | 47 | 1.5 | 2350 |
吲哚美辛 | 50 | 2.5 | 0.05 | 0.249 | 50 | 850 | 1342 | 7.05 | 47 | 1.5 | 2350 |
酮洛芬 | 100 | 2.5 | 0.05 | 0.249 | 75 | 825 | 1292 | 7.05 | 47 | 1.5 | 2350 |
甲灭酸 | 500 | 2.5 | 0.05 | 0.249 | 150 | 500 | 1142 | 7.05 | 47 | 1.5 | 2350 |
萘普生 | 250 | 2.5 | 0.05 | 0.249 | 7.5 | 680 | 1354 | 7.05 | 47 | 1.5 | 2350 |
罗非考昔 | 12.5 | 2.5 | 0.05 | 0.249 | 7.5 | 1010 | 1196 | 7.05 | 47 | 1.5 | 2350 |
吡罗昔康 | 20 | 2.5 | 0.05 | 0.249 | 15 | 950 | 1307 | 7.05 | 47 | 1.5 | 2350 |
替诺昔康 | 20 | 2.5 | 0.05 | 0.249 | 15 | 950 | 1307 | 7.05 | 47 | 1.5 | 2350 |
阿斯匹林 | 500 | 2.5 | 0.05 | 0.249 | 150 | 500 | 1142 | 7.05 | 47 | 1.5 | 2350 |
扑热息痛 | 500 | 2.5 | 0.05 | 0.249 | 150 | 500 | 1142 | 7.05 | 47 | 1.5 | 2350 |
曲普利啶盐酸盐 | 甘油(ml) | 液体葡萄糖(ml) | 羟乙基纤维素 | 柠檬酸 | 柠檬酸钠 | 糖精钠 | 矫味剂(ml) | 96%乙醇(ml) | 左薄荷脑 | 度米芬氢溴酸盐 | 着色剂 | 水 | ||
布洛芬 | 200 | 2.5 | 0.9 | 2.9 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | 至5ml |
布洛芬 | 400 | 2.5 | 0.8 | 2.8 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | 至5ml |
氟比洛芬 | 8.75 | 2.5 | 0.99 | 2.99 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | 至5ml |
右酮洛芬 | 12.5 | 2.5 | 0.99 | 2.99 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | 至5ml |
双氯芬酸钠 | 75 | 2.5 | 0.95 | 2.95 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | 至5ml |
塞米考昔 | 200 | 2.5 | 0.9 | 2.8 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | 至5ml |
吲哚美辛 | 50 | 2.5 | 0.95 | 2.95 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | 至5ml |
酮洛芬 | 100 | 2.5 | 0.95 | 2.95 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | 至5ml |
甲灭酸 | 500 | 2.5 | 0.75 | 2.75 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | 至5ml |
萘普生 | 250 | 2.5 | 0.9 | 2.9 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | 至5ml |
罗非考昔 | 12.5 | 2.5 | 0.99 | 2.99 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | 至5ml |
吡罗昔康 | 20 | 2.5 | 0.99 | 2.99 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | 至5ml |
替诺昔康 | 20 | 2.5 | 0.99 | 2.99 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | 至5ml |
阿斯匹林 | 500 | 2.5 | 0.75 | 2.75 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | 至5ml |
扑热息痛 | 500 | 2.5 | 0.75 | 2.75 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | 至5ml |
曲普利啶盐酸盐 | 乳糖 | 预胶化玉米淀粉 | 玉米淀粉 | Ac-di-sol | 硬脂酸镁 | 聚乙烯吡咯烷酮K-29-32 | 片重(mg/) | ||
舒马普坦 | 50 | 2.5 | 145.5 | 12 | 48 | 25 | 2 | 15 | 300 |
佐米曲普坦 | 2.5 | 2.5 | 193 | 12 | 48 | 25 | 2 | 15 | 300 |
曲普利啶盐酸盐 | 二氧化硅气凝胶 | 硬脂酸镁 | 碳酸钙 | 液体葡萄糖(溶胶含量) | 液体糖(溶胶含量) | 矫味剂 | 水(ml) | 聚乙烯吡咯烷酮K29-32 | 糖锭剂重(mg/) | ||
舒马普坦 | 50 | 2.5 | 0.05 | 0.249 | 50 | 850 | 1342 | 7.05 | 47 | 1.5 | 2350 |
佐米曲普坦 | 2.5 | 2.5 | 0.05 | 0.249 | 10 | 1020 | 1196 | 7.05 | 47 | 1.5 | 2350 |
曲普利啶盐酸盐 | 甘油(ml) | 液体葡萄糖(ml) | 羟乙基纤维素 | 柠檬酸 | 柠檬酸钠 | 糖精钠 | 矫味剂(ml) | 96%乙醇(ml) | 左薄荷脑 | 度米芬氢溴酸盐 | 着色剂 | 水 | ||
舒马普坦 | 50 | 2.5 | 0.95 | 2.8 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | ||
佐米曲普坦 | 2.5 | 2.5 | 0.8 | 3.0 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 |
曲普利啶盐酸盐 | 乳糖 | 预胶化玉米淀粉 | 玉米淀粉 | Ac-di-sol | 硬脂酸镁 | 聚乙烯吡咯烷酮K-29-32 | 片重(mg/) | ||
金刚烷铵 | 100 | 2.5 | 195.5 | 12 | 48 | 25 | 2 | 15 | 400 |
阿昔洛维 | 200 | 2.5 | 95.5 | 12 | 48 | 25 | 2 | 15 | 400 |
泛昔洛维 | 250 | 2.5 | 95.5 | 12 | 48 | 25 | 2 | 15 | 450 |
曲普利啶盐酸盐 | 二氧化硅气凝胶 | 硬脂酸镁 | 碳酸钙 | 液状葡萄糖(溶胶含量) | 液状糖(溶胶含量) | 矫味剂 | 水(ml) | 聚乙烯吡咯烷酮K29-32 | 锭剂重(mg/) | ||
金刚烷铵 | 100 | 2.5 | 0.05 | 0.249 | 150 | 800 | 1341 | 7.05 | 47 | 1.5 | 2350 |
阿昔洛维 | 200 | 2.5 | 0.05 | 0.249 | 150 | 700 | 1241 | 7.05 | 47 | 1.5 | 2350 |
泛昔洛维 | 250 | 2.5 | 0.05 | 0.249 | 150 | 650 | 1191 | 7.05 | 47 | 1.5 | 2350 |
曲普利啶盐酸盐 | 甘油(ml) | 液体葡萄糖(ml) | 羟乙基纤维素 | 柠檬酸 | 柠檬酸钠 | 糖精钠 | 矫味剂(ml) | 96%乙醇(ml) | 左薄荷脑 | 度米芬氢溴酸盐 | 着色剂 | 水 | ||
金刚烷铵 | 100 | 2.5 | 0.9 | 3.0 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | ||
阿昔洛维 | 200 | 2.5 | 0.9 | 2.9 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | ||
泛昔洛维 | 250 | 2.5 | 0.9 | 2.8 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 |
曲普利啶盐酸盐 | 乳糖 | 预胶化玉米淀粉 | 玉米淀粉 | Ac-di-sol | 硬脂酸镁 | 聚乙烯吡咯烷酮K-29-32 | 片重(mg/) | ||
阿代斯汀 | 8 | 2.5 | 187.5 | 12 | 48 | 25 | 2 | 15 | 300 |
西替利嗪 | 10 | 2.5 | 185.5 | 12 | 48 | 25 | 2 | 15 | 300 |
氯雷他啶 | 10 | 2.5 | 185.5 | 12 | 48 | 25 | 2 | 15 | 300 |
非索非那定 | 120 | 2.5 | 75.5 | 12 | 48 | 25 | 2 | 15 | 300 |
特非那定 | 60 | 2.5 | 145.5 | 12 | 48 | 25 | 2 | 15 | 300 |
倍他米松 | 5 | 2.5 | 190.5 | 12 | 48 | 25 | 2 | 15 | 300 |
氯马斯汀 | 1 | 2.5 | 194.5 | 12 | 48 | 25 | 2 | 15 | 300 |
溴苯盯敏 | 8 | 2.5 | 187.5 | 12 | 48 | 25 | 2 | 15 | 300 |
氯苯那敏 | 4 | 2.5 | 191.5 | 12 | 48 | 25 | 2 | 15 | 300 |
曲普利啶盐酸盐 | 氧相二氧化硅 | 硬脂酸镁 | 碳酸钙 | 液体葡萄糖(溶胶含量) | 液体糖(溶胶含量) | 矫味剂 | 水(ml) | 聚乙烯吡咯烷酮K29-32 | 锭剂重(mg/) |
阿代斯汀 | 8 | 2.5 | 0.05 | 0.249 | 10 | 1010 | 1264 | 7.05 | 47 | 1.5 | 2350 |
西替利嗪 | 10 | 2.5 | 0.05 | 0.249 | 10 | 1010 | 1262 | 7.05 | 47 | 1.5 | 2350 |
氯雷他啶 | 10 | 2.5 | 0.05 | 0.249 | 10 | 1010 | 1262 | 7.05 | 47 | 1.5 | 2350 |
非索非那定 | 120 | 2.5 | 0.05 | 0.249 | 100 | 900 | 1172 | 7.05 | 47 | 1.5 | 2350 |
特非那定 | 60 | 2.5 | 0.05 | 0.249 | 50 | 1000 | 1182 | 7.05 | 47 | 1.5 | 2350 |
倍他米松 | 5 | 2.5 | 0.05 | 0.249 | 10 | 1010 | 1267 | 7.05 | 47 | 1.5 | 2350 |
氯马斯汀 | 1 | 2.5 | 0.05 | 0.249 | 10 | 1010 | 1273 | 7.05 | 47 | 1.5 | 2350 |
溴苯盯敏 | 8 | 2.5 | 0.05 | 0.249 | 10 | 1010 | 1264 | 7.05 | 47 | 1.5 | 2350 |
氯苯那敏 | 4 | 2.5 | 0.05 | 0.249 | 10 | 1010 | 1260 | 7.05 | 47 | 1.5 | 2350 |
曲普利啶盐酸盐 | 甘油(ml) | 液体葡萄糖(ml) | 羟乙基纤维素 | 柠檬酸 | 柠檬酸钠 | 糖精钠 | 矫味剂(ml) | 96%乙醇(ml) | 左薄荷脑 | 度米芬氢溴酸盐 | 着色剂 | 水 | ||
阿代斯汀 | 8 | 2.5 | 0.9 | 2.9 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
西替利嗪 | 10 | 2.5 | 0.8 | 2.8 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
氯雷他啶 | 10 | 2.5 | 0.99 | 2.99 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
非索非那定 | 120 | 2.5 | 0.99 | 2.99 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
特非那定 | 60 | 2.5 | 0.95 | 2.95 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
倍他米松 | 5 | 2.5 | 0.9 | 2.8 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
氯马斯汀 | 1 | 2.5 | 0.95 | 2.95 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
溴苯盯敏 | 8 | 2.5 | 0.95 | 2.95 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
氯苯那敏 | 4 | 2.5 | 0.95 | 2.95 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
曲普利啶盐酸盐 | 乳糖 | 预胶化玉米淀粉 | 玉米淀粉 | Ac-di-sol | 硬脂酸镁 | 聚乙烯吡咯烷酮K-29-32 | 片重(mg/) | ||
氨溴索 | 30 | 2.5 | 165.5 | 12 | 48 | 25 | 2 | 15 | 300 |
愈创甘油醚 | 100 | 2.5 | 195.5 | 12 | 48 | 25 | 2 | 15 | 400 |
右美沙芬 | 10 | 2.5 | 185.5 | 12 | 48 | 25 | 2 | 15 | 300 |
薄荷醇 | 10 | 2.5 | 185.5 | 12 | 48 | 25 | 2 | 15 | 300 |
苯丙胺醇 | 12.5 | 2.5 | 183 | 12 | 48 | 25 | 2 | 15 | 300 |
曲普利啶盐酸盐 | 二氧化硅气凝胶 | 硬脂酸镁 | 碳酸钙 | 液体葡萄糖(溶胶含量) | 液体糖(溶胶含量) | 矫味剂 | 水(ml) | 聚乙烯吡咯烷酮K29-32 | 锭剂重(mg/) |
氨溴索 | 30 | 2.5 | 0.05 | 0.249 | 10 | 1000 | 1262 | 7.05 | 47 | 1.5 | 2350 |
愈创甘油醚 | 100 | 2.5 | 0.05 | 0.249 | 75 | 825 | 1292 | 7.05 | 47 | 1.5 | 2350 |
右美沙芬 | 10 | 2.5 | 0.05 | 0.249 | 10 | 980 | 1262 | 7.05 | 47 | 1.5 | 2350 |
薄荷醇 | 10 | 2.5 | 0.05 | 0.249 | 10 | 980 | 1262 | 7.05 | 47 | 1.5 | 2350 |
苯丙胺醇 | 12.5 | 2.5 | 0.05 | 0.249 | 10 | 978 | 1262 | 7.05 | 47 | 1.5 | 2350 |
曲普利啶盐酸盐 | 甘油(ml) | 液体葡萄糖(ml) | 羟乙基纤维素 | 柠檬酸 | 柠檬酸钠 | 糖精钠 | 矫味剂(ml) | 96%乙醇(ml) | 左薄荷脑 | 度米芬氢溴酸盐 | 着色剂 | 水 | ||
氨溴索 | 30 | 2.5 | 0.9 | 2.9 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
愈创甘油醚 | 100 | 2.5 | 0.8 | 2.8 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
右美沙芬 | 10 | 2.5 | 0.99 | 2.99 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
薄荷醇 | 10 | 2.5 | 0.99 | 2.99 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
苯丙胺醇 | 12.5 | 2.5 | 0.95 | 2.95 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
曲普利啶盐酸盐 | 乳糖 | 预胶化玉米淀粉 | 玉米淀粉 | Ac-di-sol | 硬脂酸镁 | 聚乙烯吡咯烷酮K-29-32 | 片重(mg/) |
wt(mg/) | |||||||||
苯佐卡因 | 10 | 2.5 | 185.5 | 12 | 48 | 25 | 2 | 15 | 300 |
利多卡因 | 10 | 2.5 | 185.5 | 12 | 48 | 25 | 2 | 15 | 300 |
己雷琐辛 | 2.5 | 2.5 | 193 | 12 | 48 | 25 | 2 | 15 | 300 |
短杆菌素 | 1 | 2.5 | 194.5 | 12 | 48 | 25 | 2 | 15 | 300 |
二氯苄醇 | 1.2 | 2.5 | 194.7 | 12 | 48 | 25 | 2 | 15 | 300 |
戊甲基甲酚 | 0.6 | 2.5 | 194.1 | 12 | 48 | 25 | 2 | 15 | 300 |
西波林(氯化十六烷基铵基吡啶) | 2 | 2.5 | 193.5 | 12 | 48 | 25 | 2 | 15 | 300 |
曲普利啶盐酸盐 | 曲普利啶盐酸盐 | 二氧化硅气凝胶 | 硬脂酸镁 | 碳酸钙 | 液体葡萄糖(溶胶含量) | 液体糖(溶胶含量) | 矫味剂 | 水(ml) | 聚乙烯吡咯烷酮K29-32 | 锭剂重(mg/) | |
苯佐卡因 | 10 | 2.5 | 0.05 | 0.249 | 10 | 980 | 1262 | 7.05 | 47 | 1.5 | 2350 |
利多卡因 | 10 | 2.5 | 0.05 | 0.249 | 10 | 980 | 1262 | 7.05 | 47 | 1.5 | 2350 |
己雷琐辛 | 2.5 | 2.5 | 0.05 | 0.249 | 10 | 987.5 | 1262 | 7.05 | 47 | 1.5 | 2350 |
短杆菌素 | 1 | 2.5 | 0.05 | 0.249 | 10 | 989 | 1262 | 7.05 | 47 | 1.5 | 2350 |
二氯苄醇 | 1.2 | 2.5 | 0.05 | 0.249 | 10 | 988.8 | 1262 | 7.05 | 47 | 1.5 | 2350 |
戊甲基甲酚 | 0.6 | 2.5 | 0.05 | 0.249 | 10 | 989.4 | 1262 | 7.05 | 47 | 1.5 | 2350 |
西波林(氯化十六烷基铵基吡啶) | 2 | 2.5 | 0.05 | 0.249 | 10 | 988 | 1262 | 7.05 | 47 | 1.5 | 2350 |
曲普利啶盐酸盐 | 甘油(ml) | 液体葡萄糖(ml) | 羟乙基纤维素 | 柠檬酸 | 柠檬酸钠 | 糖精钠 | 矫味剂(ml) | 96%乙醇(ml) | 左薄荷脑 | 度米芬氢溴酸盐 | 着色剂 | 水 | ||
苯佐卡因 | 10 | 2.5 | 0.9 | 2.9 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
利多卡因 | 10 | 2.5 | 0.8 | 2.8 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
己雷琐辛 | 2.5 | 2.5 | 0.99 | 2.99 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
短杆菌素 | 1 | 2.5 | 0.99 | 2.99 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
二氯苄醇 | 1.2 | 2.5 | 0.95 | 2.95 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
戊甲基甲酚 | 0.6 | 2.5 | 1.0 | 3.0 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
西波林(氯化十六烷基铵基吡啶) | 2 | 2.5 | 0.99 | 2.9 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | 0.9 | to 5ml |
曲普利啶盐酸盐 | 乳糖 | 预胶化玉米淀粉 | 玉米淀粉 | Ac-di-sol | 硬脂酸镁 | 聚乙烯吡咯烷酮K-29-32 | 片重(mg/) | ||
心得安 | 10 | 2.5 | 185.5 | 12 | 48 | 25 | 2 | 15 | 300 |
心得安 | 20 | 2.5 | 175.5 | 12 | 48 | 25 | 2 | 15 | 300 |
心得安 | 40 | 2.5 | 155.5 | 12 | 48 | 25 | 2 | 15 | 300 |
曲普利啶盐酸盐 | 二氧化硅气凝胶 | 硬脂酸镁 | 碳酸钙 | 液体葡萄糖(溶胶含量) | 液体糖(溶胶含量) | 矫味剂 | 水(ml) | 聚乙烯吡咯烷酮K29-32 | 锭剂重(mg/) | ||
心得安 | 10 | 2.5 | 0.05 | 0.249 | 10 | 980 | 1262 | 7.05 | 47 | 1.5 | 2350 |
心得安 | 20 | 2.5 | 0.05 | 0.249 | 10 | 970 | 1262 | 7.05 | 47 | 1.5 | 2350 |
心得安 | 40 | 2.5 | 0.05 | 0.249 | 10 | 950 | 1262 | 7.05 | 47 | 1.5 | 2350 |
曲普利啶盐酸盐 | 甘油(ml) | 液体葡萄糖(ml) | 羟乙基纤维素 | 柠檬酸 | 柠檬酸钠 | 糖精钠 | 矫味剂(ml) | 96%乙醇(ml) | 左薄荷脑 | 度米芬氢溴酸盐 | 着色剂 | 水 | ||
心得安 | 10 | 2.5 | 0.9 | 3.0 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | ||
心得安 | 20 | 2.5 | 0.9 | 2.9 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 | ||
心得安 | 40 | 2.5 | 0.9 | 2.8 | 12.5 | 17 | 50 | 12.5 | 0.009 | 0.1 | 1 | 0.25 |
安慰剂 | 2.5mg | 5mg | ||
(a)SDI(%) | 均值 | 均值 | 均值 | |
(睡眠潜伏期开始和 | 星斯一 | 13.19 | 11.33 | 11.72 |
睡眠质量) | 星斯二 | 14.58 | 12.15 | 12.71 |
(动作计) | 星斯三 | 14.46 | 11.2 | 11.81 |
3天均值 | 14.26 | 11.56 | 12.23 | |
(b)TTSO(min) | 均值 | 均值 | 均值 | |
(睡眠开始时间) | 星斯一 | 20.75 | 16.22 | 16.16 |
(动作计) | 星斯二 | 22.29 | 15.62 | 17.88 |
星斯三 | 20.26 | 14.8 | 16.36 | |
3天均值 | 22.16 | 15.53 | 16.93 | |
(c)醒后15分钟 | 均值 | 均值 | 均值 | |
(1-精力非常充沛) | 星斯一 | 3.41 | 3.33 | 3.72 |
5-非常疲劳) | 星斯二 | 3.46 | 3.23 | 3.56 |
(Loughborough睡眠日志) | 星斯三 | 3.42 | 3.18 | 3.54 |
3天均值 | 3.45 | 3.24 | 3.59 |
安慰剂 | 2.5mg | 5mg | ||
3天均值 | ||||
(d)昨夜的睡眠 | 均值 | 均值 | 均值 | |
1-极好, | 星斯一 | 3.2 | 2.67 | 2.49 |
5-极差) | 星斯二 | 3.06 | 2.71 | 2.93 |
(Loughborough睡眠日志) | 星斯三 | 3.02 | 2.81 | 2.64 |
3天均值 | 3.11 | 2.73 | 2.69 | |
(e)入睡的时间(min) | 均值 | 均值 | 均值 | |
(Loughborough睡眠日志) | 星斯一 | 33.61 | 23.67 | 22.02 |
星斯二 | 29.73 | 24.44 | 32.08 | |
星斯三 | 28.35 | 20.95 | 24.24 | |
3天均值 | 30.98 | 23.93 | 26.5 | |
(f)没有醒觉的时间 | 均值 | 均值 | 均值 | |
(Loughborough睡眠日志) | 星斯一 | 1.9 | 1.18 | 1.49 |
星斯二 | 1.61 | 1.37 | 1.42 | |
星斯三 | 1.43 | 1.11 | 1.39 | |
3天均值 | 1.71 | 1.22 | 1.42 |
试验日 | 星斯一 | 星斯二 | 星斯三 | |||
剂量 | N | % | n | % | n | % |
安慰剂 | 10 | 15.2 | 10 | 16.4 | 11 | 18.3 |
2.5mg由普利啶HCl·H2O | 14 | 23 | 14 | 23 | 16 | 25.8 |
5mg由普利啶HCl·H2O | 7 | 11.5 | 5 | 8.2 | 9 | 14.8 |
试验日 | 星斯一 | 星斯二 | 星斯三 | |||
剂量 | N | % | n | % | n | % |
安慰剂 | 11 | 18 | 12 | 22.2 | 13 | 24.1 |
2.5mg由普利啶HCl·H2O | 24 | 41.4 | 23 | 41.8 | 22 | 37.9 |
5mg由普利啶HCl·H2O | 30 | 50.9 | 17 | 28.8 | 24 | 39.3 |
试验日 | 星斯一 | 星斯二 | 星斯三 | |||
剂量 | n | % | n | % | n | % |
安慰剂 | 9 | 13.6 | 14 | 23.0 | 11 | 17.2 |
2.5mg由普利啶HCl·H2O | 13 | 21.3 | 13 | 21.3 | 13 | 21.0 |
5mg由普利啶HCl·H2O | 4 | 6.3 | 6 | 9.5 | 11 | 17.5 |
试验日 | 星斯一 | 星斯二 | 星斯三 | |||
剂量 | n | % | n | % | n | % |
安慰剂 | 8 | 12.1 | 10 | 16.4 | 9 | 14.1 |
2.5mg由普利啶HCl·H2O | 7 | 11.5 | 8 | 13.1 | 4 | 6.5 |
5mg由普利啶HCl·H2O | 8 | 12.5 | 11 | 17.5 | 8 | 12.7 |
Claims (71)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0312419.5 | 2003-05-30 | ||
GBGB0312419.5A GB0312419D0 (en) | 2003-05-30 | 2003-05-30 | Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1842334A true CN1842334A (zh) | 2006-10-04 |
Family
ID=9959030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2004800223860A Pending CN1842334A (zh) | 2003-05-30 | 2004-06-01 | 化合物在睡眠障碍治疗中的用途 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20070123571A1 (zh) |
EP (1) | EP1660082A1 (zh) |
CN (1) | CN1842334A (zh) |
AU (1) | AU2004319510A1 (zh) |
CA (1) | CA2524805A1 (zh) |
GB (1) | GB0312419D0 (zh) |
RU (1) | RU2354374C2 (zh) |
WO (1) | WO2005123074A1 (zh) |
ZA (1) | ZA200509669B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083643A (zh) * | 2008-03-27 | 2013-05-08 | 雀巢产品技术援助有限公司 | 增加肽、肽模拟物和其他胃肠道转运蛋白底物吸收的方法 |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
JP4839660B2 (ja) * | 2005-04-07 | 2011-12-21 | 住友化学株式会社 | チアゾール化合物の製造法 |
JP2009507854A (ja) * | 2005-09-09 | 2009-02-26 | モノソル アールエックス リミテッド ライアビリティ カンパニー | 粘着防止剤を組み込む即溶性製剤用の均一なフィルム |
EP1925305A1 (en) * | 2006-10-23 | 2008-05-28 | N.V. Organon | Ih channel inhibitors for the promotion of wakefulness |
US20120231022A1 (en) * | 2009-05-28 | 2012-09-13 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonist compounds for sleep enhancement |
US20110065655A1 (en) * | 2009-09-17 | 2011-03-17 | Karry Whitten | Therapeutic composition to treat lesions caused by herpes simplex virus |
RU2448702C2 (ru) * | 2010-07-16 | 2012-04-27 | Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" | Фармацевтическая композиция для лечения язвенной болезни желудка и/или 12-перстной кишки |
US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
US20120294952A1 (en) * | 2011-05-18 | 2012-11-22 | Zarbees, Inc. | Antitussive compositions and methods |
EP2717698A4 (en) * | 2011-06-09 | 2015-01-07 | Requis Pharmaceuticals Inc | ANTIHISTAMINES COMBINED WITH FOOD SUPPLEMENTS TO IMPROVE HEALTH |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
GB201302048D0 (en) * | 2013-02-05 | 2013-03-20 | Bennett Christopher F | Forulation with significant sedative properties for possible medical use in anxiety and a hypnotic formulation |
CN105473133A (zh) | 2013-04-30 | 2016-04-06 | 欧缇托匹克公司 | 干粉制剂及使用方法 |
JP6851365B2 (ja) | 2015-03-26 | 2021-03-31 | ジャクリーン・エム・イヴァーセン | 宿酔に伴う症状を抑制するための方法及び組成物 |
EP3452023A1 (en) | 2016-05-05 | 2019-03-13 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
KR20230040375A (ko) | 2017-09-22 | 2023-03-22 | 오티토픽 인코퍼레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
JP7260113B2 (ja) * | 2019-05-16 | 2023-04-18 | 株式会社日清製粉グループ本社 | 徐波活動促進剤 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB972128A (en) * | 1960-01-21 | 1964-10-07 | Wellcome Found | Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets |
US4783465A (en) * | 1984-04-09 | 1988-11-08 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
US5025019A (en) * | 1984-04-09 | 1991-06-18 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
US4840962A (en) * | 1984-04-09 | 1989-06-20 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
US4871733A (en) * | 1984-04-09 | 1989-10-03 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
US4552899A (en) * | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
SE8604792L (sv) * | 1986-11-07 | 1988-05-08 | Asea Atom Ab | Fiberoptisk dataoverforing vid borrhalslogging |
US20030206942A1 (en) * | 1998-09-25 | 2003-11-06 | Neema Kulkarni | Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent |
US6596298B2 (en) * | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
US20030211136A1 (en) * | 1998-09-25 | 2003-11-13 | Neema Kulkarni | Fast dissolving orally consumable films containing a sweetener |
US6245785B1 (en) * | 1998-11-30 | 2001-06-12 | Warner Lambert Company | Dissolution of triprolidine hydrochloride |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
CA2423585A1 (en) * | 2000-09-26 | 2002-04-04 | Temple University Of The Commonwealth System Of Higher Education | Analgesic and glucosamine compositions |
IL142533A0 (en) * | 2001-04-10 | 2002-03-10 | Bartoov Benjamin | Method for selecting spermatozoon |
US7355042B2 (en) * | 2001-10-16 | 2008-04-08 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
US7189757B2 (en) * | 2001-10-16 | 2007-03-13 | Hypnion, Inc. | Treatment of sleep disorders using CNS target modulators |
EP1443929A4 (en) * | 2001-10-16 | 2008-02-06 | Hypnion Inc | TREATMENT OF CNS DISTURBANCES WITH CNS TARGET MODULATORS |
-
2003
- 2003-05-30 GB GBGB0312419.5A patent/GB0312419D0/en not_active Ceased
-
2004
- 2004-06-01 EP EP04735597A patent/EP1660082A1/en not_active Withdrawn
- 2004-06-01 CN CNA2004800223860A patent/CN1842334A/zh active Pending
- 2004-06-01 US US10/557,196 patent/US20070123571A1/en not_active Abandoned
- 2004-06-01 RU RU2005137165/15A patent/RU2354374C2/ru not_active IP Right Cessation
- 2004-06-01 CA CA002524805A patent/CA2524805A1/en not_active Abandoned
- 2004-06-01 WO PCT/GB2004/002330 patent/WO2005123074A1/en active Application Filing
- 2004-06-01 AU AU2004319510A patent/AU2004319510A1/en not_active Abandoned
-
2005
- 2005-11-19 ZA ZA200509669A patent/ZA200509669B/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083643A (zh) * | 2008-03-27 | 2013-05-08 | 雀巢产品技术援助有限公司 | 增加肽、肽模拟物和其他胃肠道转运蛋白底物吸收的方法 |
CN103083643B (zh) * | 2008-03-27 | 2015-01-07 | 雀巢产品技术援助有限公司 | 增加肽、肽模拟物和其他胃肠道转运蛋白底物吸收的方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2524805A1 (en) | 2004-11-30 |
WO2005123074A1 (en) | 2005-12-29 |
WO2005123074A9 (en) | 2006-12-14 |
RU2005137165A (ru) | 2007-06-27 |
EP1660082A1 (en) | 2006-05-31 |
ZA200509669B (en) | 2006-10-25 |
AU2004319510A8 (en) | 2009-01-08 |
GB0312419D0 (en) | 2003-07-02 |
US20070123571A1 (en) | 2007-05-31 |
RU2354374C2 (ru) | 2009-05-10 |
AU2004319510A1 (en) | 2006-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1842334A (zh) | 化合物在睡眠障碍治疗中的用途 | |
CN1293878C (zh) | 眼睛疲劳或假性近视预防或治疗剂 | |
CN1309380C (zh) | 治疗代谢紊乱、特别是糖尿病或与糖尿病相关的疾病或疾患的药物 | |
CN100337613C (zh) | 泡腾颗粒及其制造方法 | |
CN1211079C (zh) | 稳定的缓释口服给药组合物 | |
CN1323663C (zh) | 含瑞波西汀的缓释片剂 | |
CN1201738C (zh) | 用于改善男性勃起机能障碍的含有阿扑吗啡的剂型 | |
CN1302605A (zh) | 缓释的口服给药组合物 | |
CN1279900C (zh) | 用于睡眠障碍的加巴喷丁类似物 | |
CN1646132A (zh) | 治疗运动疾病患者的方法 | |
CN1592622A (zh) | 含有fexofenadine的口溶性片剂 | |
CN1113436A (zh) | 药物反应的增效作用 | |
CN1087262A (zh) | 控释羟可酮组合物 | |
CN100335060C (zh) | 细胞色素p450依赖性蛋白酶抑制剂的组合物 | |
CN1897816A (zh) | 用于治疗、改善和控制疼痛的含有选择性细胞因子抑制药的组合物及其使用方法 | |
CN1642529A (zh) | 用于持续,不变且独立释放活性化合物的基质 | |
CN1165293C (zh) | 5ht4激动剂或拮抗剂的新型口服制剂 | |
CN1679525A (zh) | 复方对乙酰氨基酚口腔崩解片 | |
CN1617723A (zh) | 化合物在睡眠障碍等的治疗、在醒时使精力恢复方面的用途以及治疗与之相伴的头晕眼花的方法 | |
CN1771973A (zh) | 一种含非甾体类抗炎镇痛药的组合药物及其制备方法 | |
CN1136852C (zh) | 头孢克罗的制药用配方 | |
CN1723964A (zh) | 一种治疗咳喘、慢性支气管炎的药物 | |
CN101043879A (zh) | 钾atp通道开放剂的药物制剂及其应用 | |
CN1129429C (zh) | 钾、钠和三羟甲基氨基甲烷噁丙嗪盐药物配方 | |
CN1739677A (zh) | 一种喉疾灵新制剂及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: RECKITT BENCKISER HEALTHCARE (UK) LIMITED Free format text: FORMER OWNER: RECKITT BENCKISER HEALTHCARE INTERNATIONAL CO., LTD. Effective date: 20070119 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20070119 Address after: Beck County Applicant after: Reckitt Benckiser Healthcare Address before: British Nottingham Applicant before: Li Jie time Health International Limited |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20061004 |